American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease In New Expert | Latest News RSS feed

American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease In New Expert - Latest News


American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 ...

A new ... by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type ... read more

ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

A new ... American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with ... read more

Cardiology association recommends Lilly's Jardiance for lowering CV risk in type 2 diabetics

and alliance partner Boehringer Ingelheim announce that the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for reducing cardiovascular (CV) ... read more

Looking for another news?


Bolstering your armamentarium with SGLT2 inhibitors

Abstract: Sodium-glucose cotransporter-2 inhibitors have a unique mechanism of action in the kidneys Journal Logo Secondary Logo Account Saved Searches Recent Searches Register Activate Subscription L... read more


Type 2 Diabetes

In December 2016, FDA awarded empagliflozin a new ... reduce cardiovascular death in adults with type 2 diabetes. [Online] Available at: https:/www.fda.gov/newsevents/newsroom/pressannouncements/ucm53... read more

AstraZeneca: Q1 2017 Results

A decline of 2% (stable at CER), with growth offset by the performance of Symbicort in the US · New CVMD 5: Growth of 5% (6% at CER), with competitive pressures in the US continuing · Japan: Growth of ... read more

Eli Lilly and Co Free Cash Flow (Annual)

Security holders include debt holders, equity holders, preferred stock holders, and convertible security holders. Specifically, free cash flow is used to pay dividends, make acquisitions, develop new ... read more

Dr. Silvio Inzucchi

Silvio Inzucchi is an endocrinologist in New Haven ... He is one of 41 doctors at Yale New Haven Hospital who specialize in Endocrinology, Diabetes & Metabolism. read more

AstraZeneca: Q1 2017 Results

A decline of 2% (stable at CER), with growth offset by the performance of Symbicort in the US · New CVMD 5: Growth of 5% (6% at CER), with competitive pressures in the US continuing · Japan: Growth of ... read more

Bolstering your armamentarium with SGLT2 inhibitors

6 A recent review showed that when an SGLT2 inhibitor was added to background metformin therapy, reductions in A1C versus placebo were 0.54% to 0.77% (baseline A1C, 7.9% to 8.2 ... College of Endocrin... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us